TY - JOUR
T1 - Adapting fasting plasma glucose threshold for GDM diagnosis according to the population distribution - an approach to the Danish paradox
AU - Christian Jensen, Richard
AU - Møller Jensen, Dorte
AU - Gibbons, Kristen S
AU - Glintborg, Dorte
AU - Kold Jensen, Tina
AU - David McIntyre, H
AU - Andersen, Marianne
N1 - Copyright © 2021 Elsevier B.V. All rights reserved.
PY - 2021/4/22
Y1 - 2021/4/22
N2 - Aims: To examine third trimester fasting venous plasma glucose (FVPG) according to the distribution of a Danish population of pregnant women and identify potential local FVPG thresholds for GDM diagnosis related to risks of adverse pregnancy outcomes. Methods: In the observational Odense Child Cohort (OCC) study, 1516 women had FVPG measured at 27–28 weeks’ gestation and were considered normal by Danish criteria and remained untreated. Maternal FVPG from OCC were standardized according to the local FVPG mean and standard deviation calibrated to data from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study. Associations between maternal FVPG and clinical and anthropometric outcomes were analysed. Potential FVPG cut points were identified. Results: Unadjusted areas under the ROC curve for FVPG to discriminate for large for gestational age (LGA) and hypertensive disorders of pregnancy were 0.61 (95% CI 0.56, 0.67) and 0.57 (95% CI 0.52, 0.63), respectively. The Youden FVPG cut point for LGA was 5.5 mmol/L and 5.0 mmol/L for hypertensive disorders of pregnancy. Conclusions: This study identified a potential locally appropriate third trimester FVPG cut point between 5.5 and 5.7 mmol/L based on LGA risk in pregnancy. This cut point should be validated prospectively in other Danish cohorts.
AB - Aims: To examine third trimester fasting venous plasma glucose (FVPG) according to the distribution of a Danish population of pregnant women and identify potential local FVPG thresholds for GDM diagnosis related to risks of adverse pregnancy outcomes. Methods: In the observational Odense Child Cohort (OCC) study, 1516 women had FVPG measured at 27–28 weeks’ gestation and were considered normal by Danish criteria and remained untreated. Maternal FVPG from OCC were standardized according to the local FVPG mean and standard deviation calibrated to data from the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study. Associations between maternal FVPG and clinical and anthropometric outcomes were analysed. Potential FVPG cut points were identified. Results: Unadjusted areas under the ROC curve for FVPG to discriminate for large for gestational age (LGA) and hypertensive disorders of pregnancy were 0.61 (95% CI 0.56, 0.67) and 0.57 (95% CI 0.52, 0.63), respectively. The Youden FVPG cut point for LGA was 5.5 mmol/L and 5.0 mmol/L for hypertensive disorders of pregnancy. Conclusions: This study identified a potential locally appropriate third trimester FVPG cut point between 5.5 and 5.7 mmol/L based on LGA risk in pregnancy. This cut point should be validated prospectively in other Danish cohorts.
KW - Adverse pregnancy outcomes
KW - Gestational diabetes mellitus
KW - Glucose tolerance
KW - Large for gestational age
KW - Offspring anthropometrics
U2 - 10.1016/j.diabres.2021.108832
DO - 10.1016/j.diabres.2021.108832
M3 - Journal article
C2 - 33895195
SN - 0168-8227
VL - 175
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
M1 - 108832
ER -